Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing …